English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objectives. Prostate-specific antigen (PSA) is the most used and validated marker of prostate cancer risk. The aim of this study was to assess PSA levels during treatment with testosteronum undecanoat in patients with type 2 diabetes (T2DM). Material and Methods. We evaluated 38 T2DM patients aged between 48 and 61 years with confirmed hypogonadism. 1000 mg testosterone undecanoate was injected intramuscular every 10 to 14 weeks. Total testosterone and PSA levels were assessed at baseline and after 6, 12, 24 months of treatment. Results. The average age was 55.03 ± 2.40 years and 3 patients (7.89%) had a family history of prostate cancer. Treatment with testosterone undecanoate generated significant changes in serum total testosterone (482.29±50.78 ng/dl vs. 246.66±51.50 ng/dl, p < 0.001) but not in serum PSA levels (2.11±.0.49 ng/ml vs. 2.09±0.47 ng/ml, p - NS). Conclusion. Testosterone replacement therapy may normalize serum androgen levels but appears to have little effect on PSA levels.

Dynamics of Prostate-Specific Antigen Levels During Treatment with Testosterone Undecanoate in Patients with Type 2 Diabetes Mellitus